# Corcept Therapeutics Incorporated (CORT)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $9.99B  
**Price:** $83.28 (+6.61%)

> Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing medications that address severe endocrine, metabolic, oncologic, and neurologic disorders. The company’s core scientific approach is based on modulating the effects of the hormone cortisol, which plays a central role in multiple disease pathways. Corcept Therapeutics today develops therapies for conditions such as hypercortisolism and is evaluating compounds in clinical settings for advanced ovarian and prostate cancers, amyotrophic lateral sclerosis (ALS), and metabolic dysfunction-associated steatohepatitis (MASH). Its portfolio is centered on proprietary cortisol modulators designed to offer targeted treatment options where existing therapies may be limited. Corcept Therapeutics markets its products primarily to healthcare providers and specialty treatment centers managing complex endocrine and oncologic conditions. Founded in 1998 and headquartered in Redwood City, California, the company operates within the broader health technology and major pharmaceuticals industry, contributing specialized expertise in cortisol biology to address serious, difficult-to-treat diseases.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $761M | $748M | $45M | $100M | — |
| 2024 | $675M | $664M | $137M | $141M | — |
| 2023 | $482M | $476M | $107M | $106M | — |
| 2022 | $402M | $396M | $113M | $101M | — |
| 2021 | $366M | $361M | $124M | $113M | — |
| 2020 | $354M | $348M | $128M | $106M | — |
| 2019 | $306M | $301M | $112M | $94M | — |
| 2018 | $251M | $246M | $89M | $75M | — |
| 2017 | $159M | $156M | $53M | $129M | — |
| 2016 | $81M | $79M | $10M | $8M | — |
| 2009 | $29,000 | — | -$20M | -$20M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $837M | $189M | $648M | $120M | — |
| 2024 | $841M | $161M | $680M | $128M | — |
| 2023 | $622M | $115M | $507M | $136M | — |
| 2022 | $583M | $82M | $502M | $66M | — |
| 2021 | $424M | $48M | $376M | $78M | — |
| 2020 | $572M | $48M | $523M | $76M | — |
| 2019 | $412M | $41M | $371M | $31M | — |
| 2018 | $312M | $36M | $276M | $42M | — |
| 2017 | $221M | $30M | $191M | $31M | — |
| 2016 | $69M | $27M | $41M | $52M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $142M | $211,000 | $142M |
| 2024 | $198M | $2M | $196M |
| 2023 | $127M | $139,000 | $127M |
| 2022 | $120M | $413,000 | $120M |
| 2021 | $168M | $469,000 | $167M |
| 2020 | $152M | $1M | $151M |
| 2019 | $136M | $1M | $135M |
| 2018 | $116M | $298,000 | $115M |
| 2017 | $61M | $419,000 | $61M |
| 2016 | $18M | $194,000 | $18M |
| 2013 | -$37M | $127,000 | -$37M |
| 2012 | -$36M | $151,000 | -$36M |
| 2011 | -$27M | $25,000 | -$27M |
| 2010 | -$22M | — | — |
| 2009 | -$18M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/CORT)